Congratulations to Christian M. Capitini, MD, for his recent award of $100,000 from the Midwest Athletes Against Childhood Cancer (MACC fund) for “Inhibiting STAT1 as a platform for GVHD resistance and preservation of GVL.” This project takes a novel approach toward separating GVL from GVHD by not treating T cells, but rather focusing on 2 other fundamental contributors of GVHD – cytokines and APCs. Completion of this project will provide evidence in relevant preclinical alloBMT models that using bone marrow-derived cells deficient in STAT1 will create a state of GVHD resistance, allowing the host to tolerate higher doses of DLI, potentially allowing for a more potent GVL effect.